

Press release

## **Strike Pharma receives Eurostars grant for a novel *in vivo* CAR-T project in collaboration with AbClon Inc.**

**Lund, February, 2026: Strike Pharma, ("Strike") a Swedish biotech with a proprietary technology for targeted delivery of nanoparticles, has announced that it has received acceptance for a Eurostars grant totalling up to 1 MEUR for the development of StAb19, a next generation CD19 *in vivo* CAR-T for cancer and autoimmune disease, in collaboration with the South Korean biotech AbClon Inc.**

*"This funding from Europe's most competitive funding program for small and medium sized biotech companies validates the novelty of the next generation in vivo CAR-T therapy StAb19. Being top ranked reflects the synergies between Strike's and AbClon's respective technology platforms in developing a drug candidate with potential for increased utility and superior efficacy in patients with cancer or autoimmune disease."* says Per Norlén, CEO at Strike.

Strike Pharma is leading the consortium, which builds on the two companies' respective technologies: Strike's proprietary technology for targeted lipid nanoparticle delivery and AbClon's next generation CD19 CAR for long-lasting T-cell activation. The total grant totals up to 1 MEUR, of which Strike can receive up to 5 MSEK, intended to support the optimization of StAb19 as well as proof-of-concept studies and a strong IND-enabling data package supporting clinical studies within 18 months after the 27-month project ends.

As a follow-up to the Eurostars approval of the master project, AbClon is currently undergoing a domestic evaluation process in Korea. Once the evaluation results are finalized, the company is expected to receive national funding and officially commence the project in the second half of 2026

*"AbClon is currently conducting a pivotal Phase 2 clinical trial for Nespecabtagene autoleucel (nespe-cel), an innovative autologous CD19 CAR-T therapy developed using our proprietary antibody. We anticipate nespe-cel's imminent market entry, as it has demonstrated superior efficacy compared to existing autologous CD19 CAR-T therapies—a success we believe is rooted in the unique properties of our proprietary antibody. By leveraging this same antibody in collaboration with Strike Pharma to develop an in vivo CAR-T therapy, we are confident that we can provide an 'off-the-shelf' treatment solution, ultimately delivering life-changing benefits to a significantly broader range of patients",* says Jong-Seo Lee, CEO at AbClon.

### **About Eurostars**

Eurostars is an international funding program for collaborative R&D projects led by innovative small- and medium-sized biotech companies. The grants are shared between the companies through the respective national bodies, Vinnova in Sweden and KIAT in Korea.

**About Strike Pharma AB**

Strike Pharma is a private Swedish biotech company with a proprietary technology for targeted delivery of lipid nanoparticles (LNPs), enabling *in vivo* CAR therapies. The technology builds on the adaptive conjugation of antibodies to LNPs which allows for separate storage and manufacturing of the two entities, potentially extending shelf-life, reducing manufacturing costs and boosting efficacy. The company applies its technology for the selective delivery of LNPs to T cells and myeloid cells via its emerging pipeline of *in vivo* CAR-T and *in vivo* CAR-M therapies.

Website: <https://strikepharma.com/>

Contact: Per Norlén, CEO  
[per.norlen@strikepharma.com](mailto:per.norlen@strikepharma.com)

Address: Strike Pharma c/o, SmiLe Venture Hub, Scheeleorget 1, Medicon Village, 223 81 Lund, Sweden